Global NGS-Based RNA-Sequencing Market Growth, Share, Size, Trends and Forecast (2025 - 2031)

Global NGS-Based RNA-Sequencing Market, Segmentation by Product

The Global NGS-Based RNA-Sequencing Market has been segmented by Product into RNA Sequencing Platforms & Consumables, Sample Preparation Products, RNA Sequencing Services, and Data Analysis.

The global NGS-based RNA-sequencing market is poised for significant growth between 2024 and 2030, driven by advancements in technology, increasing applications, and expanding end-user demand. Among products, RNA sequencing platforms and consumables hold a substantial share, propelled by the growing availability of advanced platforms and the rising use of consumables. Sample preparation products are crucial as they constitute the first step in the NGS workflow, encompassing library preparation, target enrichment, and quality control. The segment's growth is fueled by the need for efficient and accurate sample preparation methods, which include manual, microfluidic, and robotic liquid handling. The rising demand for services due to the lack of infrastructure and expertise among end-users also contributes to market expansion. Additionally, the integration of cloud computing and bioinformatics in data analysis, storage, and management is significantly enhancing the capabilities and growth prospects of the market.

Technological advancements are a key driver of the market, with various sequencing methods such as sequencing by synthesis, ion semiconductor sequencing, single-molecule real-time sequencing, and nanopore sequencing offering diverse benefits. These technologies are enhancing the accuracy, speed, and cost-effectiveness of RNA sequencing, thereby broadening its applications. In terms of application, the market covers expression profiling analysis, small RNA sequencing, de novo transcriptome assembly, and variant calling & transcriptome epigenetics. These applications are increasingly adopted in various research and clinical settings, reflecting the versatility and utility of RNA sequencing in understanding gene expression, identifying novel transcripts, and exploring epigenetic modifications.

The end-user segment of the market is diverse, including research and academia, hospitals and clinics, pharmaceutical and biotechnology companies, and other end users. Research and academia represent a significant share due to the extensive use of RNA sequencing in basic and translational research. Hospitals and clinics are leveraging RNA sequencing for diagnostic and therapeutic purposes, particularly in precision medicine. Pharmaceutical and biotechnology companies utilize RNA sequencing for drug discovery and development, while other end users include agricultural and environmental sectors.

Global NGS-Based RNA-Sequencing Market, Segmentation by Technology

The Global NGS-Based RNA-Sequencing Market has been segmented by Technology into Sequencing By Synthesis, Ion Semiconductor Sequencing, Single-Molecule Real-Time Sequencing, and Nanopore Sequencing.

The Global NGS-Based RNA-Sequencing Market is experiencing significant growth, driven by advancements in sequencing technologies. The market is segmented into several categories based on the technology employed, each offering unique benefits and applications. One of the primary segments is Sequencing By Synthesis (SBS), which is the most widely used technology in RNA sequencing. SBS technology, exemplified by Illumina platforms, allows for high-throughput sequencing with exceptional accuracy and efficiency. This technology has become the gold standard in RNA sequencing, providing researchers with comprehensive insights into gene expression and transcriptomics.

Another significant segment in the NGS-Based RNA-Sequencing Market is Ion Semiconductor Sequencing. This technology leverages semiconductor chips to detect hydrogen ions released during the polymerization of DNA, thus enabling real-time sequencing. Ion semiconductor sequencing is known for its speed and cost-effectiveness, making it an attractive option for smaller labs and clinical applications. It offers a balance between throughput and affordability, catering to various research and diagnostic needs. Companies like Thermo Fisher Scientific have developed robust platforms based on this technology, further driving its adoption.

Single-Molecule Real-Time (SMRT) Sequencing, developed by Pacific Biosciences, represents another critical segment. SMRT sequencing captures real-time data by monitoring the synthesis of DNA molecules as they are replicated. This technology excels in providing long read lengths and high accuracy, particularly useful for detecting complex genetic variations and RNA isoforms. SMRT sequencing's ability to produce long reads without amplification enhances the understanding of transcript structures and gene regulation mechanisms, making it invaluable for comprehensive RNA sequencing studies.

Global NGS-Based RNA-Sequencing Market, Segmentation by Application

The Global NGS-Based RNA-Sequencing Market has been segmented by Application into Expression Profiling Analysis, Small RNA Sequencing, De Novo Transcriptome Assembly, and Variant Calling & Transcriptome Epigenetics.

The Global NGS-Based RNA-Sequencing Market is witnessing rapid growth, driven by technological advancements and increasing research activities in genomics and transcriptomics. The market is segmented by application into four primary categories: Expression Profiling Analysis, Small RNA Sequencing, De Novo Transcriptome Assembly, and Variant Calling & Transcriptome Epigenetics. Each segment plays a crucial role in understanding genetic and molecular mechanisms, aiding in the development of personalized medicine, and advancing biological research.

Expression Profiling Analysis is a significant segment in the RNA-sequencing market. This application involves measuring the expression levels of a large number of genes simultaneously to understand the cellular responses under various conditions. Researchers and healthcare professionals use expression profiling to identify disease biomarkers, understand disease mechanisms, and monitor the effects of therapeutic interventions. The increasing focus on precision medicine and the need for comprehensive genomic data in disease diagnosis and treatment are propelling the demand for expression profiling analysis.

Small RNA Sequencing is another vital segment, focusing on the sequencing of small RNA molecules such as microRNAs (miRNAs) and small interfering RNAs (siRNAs). These small RNAs play crucial roles in gene regulation, development, and disease pathogenesis. Small RNA sequencing helps in identifying and quantifying these molecules, providing insights into gene expression regulation and epigenetic modifications. The growing interest in RNA-based therapies and the rising prevalence of cancer and other genetic disorders are driving the growth of this market segment.

Global NGS-Based RNA-Sequencing Market, Segmentation by End User

The Global NGS-Based RNA-Sequencing Market has been segmented by End User into Research & Academia, Hospitals & Clinics, Pharmaceutical & Biotechnology Companies, and Other End Users.

The Global NGS-Based RNA-Sequencing Market has witnessed significant segmentation based on the end-user category, reflecting the diverse applications and demand for RNA sequencing technologies across various sectors. Research & Academia stands out as a major segment, driven by the increasing adoption of next-generation sequencing (NGS) for genomic research, transcriptomics, and molecular biology studies. Academic institutions and research organizations utilize NGS-based RNA sequencing to gain deeper insights into gene expression patterns, alternative splicing events, and the discovery of novel RNA species. The growing focus on personalized medicine and the need for advanced research tools further propel the demand in this segment.

Hospitals & Clinics represent another crucial end-user segment in the NGS-based RNA-sequencing market. The integration of RNA sequencing into clinical settings has revolutionized diagnostics and therapeutic strategies. It aids in the precise diagnosis of genetic disorders, identification of biomarkers for various diseases, and the development of targeted therapies. The increasing prevalence of cancer and other chronic diseases has necessitated the adoption of advanced sequencing technologies in hospitals and clinics to enhance patient care through more accurate and timely diagnoses, contributing to the growth of this market segment.

Pharmaceutical & Biotechnology Companies are also significant contributors to the NGS-based RNA-sequencing market. These companies leverage RNA sequencing technologies in drug discovery, development, and pharmacogenomics. The ability to analyze gene expression profiles and understand the molecular mechanisms of diseases enables these companies to identify potential drug targets and develop more effective therapeutics. The rising investment in biotechnology research and the growing trend of precision medicine are key factors driving the adoption of NGS-based RNA sequencing in this segment.

Drivers

• Technological advancements in NGS platforms
• Increasing demand for personalized medicine

• Growing research in transcriptomics - The global NGS (Next-Generation Sequencing)-based RNA-Sequencing market is experiencing significant growth, driven by the expanding field of transcriptomics. Transcriptomics, the study of RNA transcripts produced by the genome under specific circumstances or in a specific cell, is crucial for understanding gene expression patterns and functional genomics. The increasing application of RNA-Sequencing in transcriptomics research is propelling the market forward. Researchers are utilizing NGS-based RNA-Sequencing to explore the complexity of the transcriptome, leading to discoveries that can enhance our understanding of diseases, developmental biology, and the intricate regulatory mechanisms of gene expression.

  Advancements in NGS technology have revolutionized RNA-Sequencing by providing high-throughput, accurate, and cost-effective solutions. This technological progress has enabled more comprehensive and detailed analyses of transcriptomes. NGS-based RNA-Sequencing offers numerous advantages, including the ability to detect novel transcripts, alternative splicing events, and post-transcriptional modifications. These capabilities are essential for identifying biomarkers, understanding disease mechanisms, and developing targeted therapies. As a result, the demand for NGS-based RNA-Sequencing in research institutions, pharmaceutical companies, and clinical laboratories is rapidly increasing.

  The market is also benefiting from substantial investments in genomics research and personalized medicine. Governments, academic institutions, and private organizations are allocating significant resources to advance RNA-Sequencing technologies and their applications. Collaborations and partnerships between key stakeholders are fostering innovation and accelerating the adoption of NGS-based RNA-Sequencing. Furthermore, the declining costs of sequencing and the availability of user-friendly bioinformatics tools are making these technologies more accessible to a broader range of researchers and clinicians, thereby expanding the market's reach.

Restraints

• High initial investment and operational costs
• Data privacy and security concerns

• Limited skilled professionals - The global NGS (Next-Generation Sequencing)-based RNA-sequencing market is experiencing significant growth, driven by the increasing interest and research in transcriptomics. Transcriptomics, the study of RNA transcripts produced by the genome, provides a deeper understanding of gene expression and regulation. NGS-based RNA-sequencing has become a crucial tool in this field due to its ability to provide high-throughput and precise data on RNA molecules. This technology allows researchers to capture a snapshot of the transcriptome, offering insights into cellular functions and disease mechanisms.

  One of the main drivers of the NGS-based RNA-sequencing market is the expanding application of transcriptomics in various fields such as oncology, immunology, and plant biology. In oncology, for instance, RNA-sequencing helps identify cancer-specific transcripts and mutations, leading to the development of targeted therapies and personalized medicine. Immunologists use RNA-sequencing to study immune responses and discover new biomarkers, which are critical for the development of vaccines and treatments for infectious diseases. Additionally, in plant biology, RNA-sequencing aids in understanding plant development and stress responses, which is essential for improving crop yields and resilience.

  Technological advancements and decreasing costs of NGS are also contributing to market growth. The development of more efficient and cost-effective sequencing platforms has made NGS-based RNA-sequencing more accessible to researchers and institutions worldwide. Companies in the genomics sector are continuously innovating to enhance the accuracy, speed, and scalability of sequencing technologies. These advancements not only make RNA-sequencing more affordable but also expand its application to larger and more diverse studies, further driving the market forward.

Opportunities

• Expanding applications in diagnostics and therapeutics
• Growing use in agricultural and environmental research

• Increasing collaborations and partnerships - The global next-generation sequencing (NGS)-based RNA-sequencing market has experienced a significant surge in recent years, largely driven by increasing collaborations and partnerships among key industry players. These strategic alliances are designed to enhance technological capabilities, broaden service offerings, and expedite the development of innovative solutions. Companies are joining forces to leverage each other's strengths, resources, and expertise, which has led to accelerated advancements in RNA-sequencing technologies and applications. This trend is particularly evident in sectors such as healthcare, pharmaceuticals, and biotechnology, where the demand for precise and comprehensive genetic data is paramount.

  A key factor fueling these partnerships is the growing need for comprehensive genomic data to support precision medicine initiatives. By collaborating, companies can pool their data, technology, and expertise to develop more robust and accurate RNA-sequencing solutions. For example, recent partnerships have focused on improving data integration and analysis, enhancing the accuracy of sequencing technologies, and reducing the time and cost associated with RNA sequencing. These collaborations often involve not just private companies but also academic institutions and research organizations, creating a multi-faceted approach to tackling the complexities of genetic research.

  Another significant driver of collaborations in the NGS-based RNA-sequencing market is the desire to expand market reach and customer base. By forming strategic alliances, companies can access new markets and customer segments that would be challenging to penetrate independently. This expansion is particularly crucial in emerging markets, where there is a growing interest in genetic research and personalized medicine. Partnerships enable companies to navigate regulatory landscapes more efficiently, share market insights, and distribute innovative products and services more effectively. Consequently, these collaborations are instrumental in driving the global adoption of RNA-sequencing technologies.